NCT06265688 - First In Human Study of CX-2051 in Advanced Solid Tumors | Biotech Hunter

Enrollment

124

Participants

Timeline

Start Date

April 2, 2024

Primary Completion Date

November 30, 2027

Study Completion Date

March 31, 2029

Conditions

Solid Tumor, Adult

Interventions

DRUG

CX-2051

Investigational drug monotherapy

Trial Locations (4)

RECRUITING

Carolina BioOncology Institute, PLLC, Huntersville

RECRUITING

Sarah Cannon Research Institute, LLC, Nashville

RECRUITING

Sarah Cannon Research Institute at HealthONE, Denver

RECRUITING

Dana-Farber Cancer Institute, Boston